Liberate Medical

Executive Summary

Liberate Medical is a privately held medical device company developing the VentFree Respiratory Muscle Stimulator, a novel neuromuscular electrical stimulation technology aimed at reducing respiratory muscle atrophy and weaning time for mechanically ventilated patients. The device non-invasively contracts and exercises the abdominal muscles, addressing the critical issue of ventilator-induced diaphragm dysfunction, which prolongs ICU stays and increases complications. By facilitating earlier liberation from mechanical ventilation, VentFree has the potential to improve patient outcomes, reduce healthcare costs, and address a significant unmet need in critical care. The company is headquartered in Grand Rapids, Michigan, and has been operating since 2014, though it remains in a pre-commercial stage with no publicly disclosed funding rounds or revenue. The respiratory device market is sizable, with mechanical ventilation used in millions of patients annually, and VentFree offers a differentiated approach compared to existing diaphragm pacing or pharmacological interventions. Liberate Medical's technology could capture meaningful market share if clinical validation and regulatory clearance are achieved. However, as a private company with limited public information, execution risk remains, and the path to commercialization will depend on successful regulatory submissions, clinical evidence generation, and securing distribution partnerships.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Submission for VentFree75% success
• Q1 2027Publication of Pivotal Clinical Trial Results60% success
• Q2 2027FDA 510(k) Clearance and US Market Entry55% success